TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17440642
Drug: Broad-spectrum immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum immune modulatory therapy
Study: 15116072
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high intake of zinc (811 micromol/day; 53 mg/day)
Study: 15116072
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary zinc (45.9 micromol/day; 3 mg/day)
Study: 15116072
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary zinc (811 micromol/day; 53 mg/day)
Study: 8088198
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (C)
Study: 2733993
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral colchicine (1.2 mg/day)
Study: 2733993
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg/day orally)
Study: 31660788
Drug: General Anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anaesthesia (GA) with tumescent anaesthesia (G + T)
Study: 24021298
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stable dosage of dopaminomimetic drugs only)
Study: 21294931
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (VAS) 50,000 IU (15 mg) at birth
Study: 14675268
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once a morning
Study: 14675268
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once a morning
Study: 14675268
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once a morning
Study: 3157709
Drug: 2% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% erythromycin ointment
Study: 27106640
Drug: 24-hour antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour antibiotic group
Study: 27106640
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic group
Study: 24806263
Drug: Zaleplon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (10 mg/day)
Study: 18403946
Drug: Ginger (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1200 mg)
Study: 10634827
Drug: simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin + omega-3 fatty acids at 3.36 g/d
Study: 8939178
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg four times daily for 12 weeks
Study: 8939178
Drug: Albuterol 0.2
Normalized name: albuterol 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 0.2 mg four times daily for 12 weeks
Study: 1382927
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy (by rapid venesection, venous infusion of autologous plasma and 500 ml dextran 40)
Study: 1382927
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy and Standard therapy
Study: 31272313
Drug: Moderate number
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate number of ARV drug changes (up to 2 per 6 months)
Study: 26473333
Drug: High-dose TwHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TwHF (2.0 mg·kg·d)
Study: 26473333
Drug: Low-dose TwHF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TwHF (1.5 mg·kg·d)
Study: 26473333
Drug: Mesalazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (3 g/d)
Study: 21586714
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (7000 μg of retinol equivalents as retinyl palmitate)
Study: 21586714
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene supplementation (42 mg of all-trans beta carotene)
Study: 14688378
Drug: CML66-L peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CML66-L peptide
Study: 14688378
Drug: CML66-L
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: CML66-L
Study: 8160279
Drug: IgM-enriched immunoglobulin
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulin (5 ml/kg/d for three days)
Study: 8160279
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with antibiotics and fresh plasma/whole blood transfusions)
Study: 29488676
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone or in combination with oral hypoglycaemic drugs; prescribed to 24.4% to 34.5% of patients with diabetes.
Study: 29488676
Drug: Insulin prescription
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin prescription in the administrative registry.
Study: 24708643
Drug: Semi-standardised acupuncture
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-standardised acupuncture plus rescue medication (cetirizine)
Study: 24708643
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus rescue medication (cetirizine)
Study: 24708643
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (cetirizine) alone
Study: 23046781
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) with written accounts (WA) component
Study: 24509894
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (80 IU a day)
Study: 22216936
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Project Toward No Drug Abuse)
Study: 15345791
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estrogen)
Study: 15345791
Drug: Reinstitution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstitution of estrogen or initiation/increase in antidepressant dose
Study: 15345791
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of hormone therapy
Study: 15345791
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estrogen) or selective estrogen receptor modulator
Study: 10439645
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg·kg‐1
Study: 10439645
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg·kg‐1
Study: 7598439
Drug: WHO/UNICEF oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO/UNICEF oral rehydration solution (ORS)
Study: 7598439
Drug: Fermented maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented maize solution
Study: 7598439
Drug: Unfermented maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfermented maize solution
Study: 28824012
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g of CLA daily for 3 months
Study: 28824012
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil as placebo daily for 3 months
Study: 19058760
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Labetalol and Lisinopril combined)
Study: 7741285
Drug: Thiobarbiturate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiobarbiturate (5 mg/kg thiopental or thiamylal)
Study: 7741285
Drug: Oxybarbiturate (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybarbiturate (1.75 mg/kg methohexital)
Study: 7741285
Drug: Thiobarbiturate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiobarbiturate (5 mg/kg)
Study: 2201652
Drug: Acetyl-L-carnitine (LAC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (LAC) 2 g/day
Study: 6259941
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing polymyxin, neomycin and bacitracin (PNB)
Study: 6259941
Drug: Iodophor ointment
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodophor ointment (PI2)
Study: 6259941
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical agent (Control)
Study: 27845030
Drug: Ultrasound-guided capsule-preserved
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided capsule-preserved hydrodilatation with corticosteroid (1mL of 40mg/mL triamcinolone acetonide, 6mL of 1% lidocaine, and normative saline)
Study: 27845030
Drug: Ultrasound-guided IACI
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided IACI alone (1mL of 40mg/mL triamcinolone acetonide and 3mL of 1% lidocaine)
Study: 26353875
Drug: Intranasal 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 2% mupirocin plus topical antisepsis with chlorhexidine gluconate for 5 days
Study: 26353875
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment and placebo cloths for skin antisepsis for 5 days
Study: 21890077
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DESs) in patients with normal GFR (≥60 ml/min/1.73 m²)
Study: 21890077
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DESs) in patients with low GFR (<60 ml/min/1.73 m²)
Study: 21890077
Drug: Bare-metal stents
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stents in patients with low GFR (<60 ml/min/1.73 m²)
Study: 21890077
Drug: Bare-metal stents
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stents in patients with normal GFR (≥60 ml/min/1.73 m²)
Study: 15328386
Drug: VML 588
Approvals — FDA: no, EMA: no, PMDA: no
Description: VML 588 (0.05, 0.20 and 0.40 mg/kg/h)
Study: 11418315
Drug: 90Y Zevalin
Normalized name: Zevalin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90Y Zevalin (0.4 mCi/kg therapeutic dose after 5 mCi tracer dose)
Study: 11418315
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 weekly x 4)
Study: 29728552
Drug: No laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laser therapy (Control)
Study: 24740207
Drug: rs705117 SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs705117 SNP (G allele)
Study: 21388079
Drug: Hydroxyzine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 75 mg
Study: 10913225
Drug: Arachidonic acid
Normalized name: Arachidonic acid
DrugBank: Arachidonic Acid (DB04557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arachidonic acid (AA) 300 mg
Study: 10913225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AA (300 mg), EPA (110 mg), and DHA (400 mg)
Study: 1526683
Drug: Cefodizime (CDZ)
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (CDZ) 2 g i.v. once daily for seven days
Study: 1526682
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1 g daily i.v. for one week (Control)
Study: 29672831
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg retigabine
Study: 26969416
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 to 40 mg
Study: 26969416
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 to 40 mg
Study: 26969416
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 and 40 mg
Study: 24207098
Drug: Intra-arterial clot
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial clot retrieval with the Solitaire FR device after intravenous tissue plasminogen activator
Study: 18724539
Drug: gemcitabine (Gemzar)
Normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine (Gemzar) plus 3 mg/kg of infliximab (Remicade)
Study: 18724539
Drug: gemcitabine (Gemzar)
Normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine (Gemzar) plus 5 mg/kg of infliximab (Remicade)
Study: 16521701
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1,800 mg/d with vitamin E 300 mg/d and vitamin C 600 mg/d
Study: 16521701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin E 300 mg/d and vitamin C 600 mg/d without EPA)
Study: 654296
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of biguanide treatment
Study: 30621974
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + ticagrelor
Study: 30621974
Drug: Registry cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry cohort (Aspirin + clopidogrel)
Study: 26324329
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg/day add-on to dapagliflozin plus metformin
Study: 26324329
Drug: Placebo add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add-on to dapagliflozin plus metformin
Study: 24929184
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol apple puree (25 mg epicatechin)
Study: 24929184
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol apple puree (100 mg epicatechin)
Study: 20828648
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg)
Study: 23033226
Drug: Pharmacist-led warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led warfarin self-management program
Study: 17641565
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (minimum of four needles, electroacupuncture preferred, strong electrical stimulation to needles placed in muscle, course of at least 10 treatments)
Study: 15882556
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg/day
Study: 12522677
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with carboplatin plus ACNU (arm A)
Study: 12522677
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with cisplatin plus BCNU (arm B)
Study: 7664215
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 to 100 mg once daily
Study: 7664215
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily + 12.5 mg HCTZ
Study: 2693078
Drug: X‐Prep (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: X‐Prep (a Senna preparation) combined with an enema
Study: 354042
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily doses of acebutolol
Study: 354042
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acebutolol with chlorexolone
Study: 18353666
Drug: DHB 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHB 1.25 mg i.v.
Study: 12095953
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet intervention (n=58); weekly cooking course for 1 year, trained by professional chefs in the use of natural ingredients.
Study: 6657201
Drug: Ascorbate or
Normalized name: Sodium Ascorbate Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbate or citrate (orthomolecular therapy)
Study: 16213057
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets containing felodipine under fed conditions
Study: 16213057
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets containing felodipine under fasting conditions
Study: 16213057
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets containing felodipine
Study: 9952138
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous ondansetron (prophylaxis)
Study: 9952138
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment with 1 mg intravenous ondansetron (if necessary)
Study: 7573905
Drug: Pentazocine 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.40 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group P/M)
Study: 7573905
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K25/M)
Study: 7573905
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K50/M)
Study: 6961763
Drug: Labetalol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (mean daily dose 636 mg)
Study: 6961763
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean dose 276 mg)
Study: 27612922
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (4 mg), PRN regimen
Study: 27612922
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (Ozurdex), single injection
Study: 23800946
Drug: l-menthol
Normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-menthol
Study: 23042771
Drug: Low-dose thoracic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thoracic computed tomography (performed in the first and sixth years)
Study: 21693030
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg/day from cycle day 1 to 9
Study: 21693030
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg/day from cycle day 3 to 7
Study: 24884651
Drug: Increased therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased therapy time (from 8.6 to at least 13 hours a week) with interventions focused on strength, mobility, and balance.
Study: 24884651
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy according to the Dutch stroke Guideline.
Study: 23311172
Drug: Compound granule
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound granule prescription of thunberg fritillary bulb
Study: 12461391
Drug: OP‐1 Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP‐1 Implant
Study: 22544644
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide over 60 min
Study: 22544644
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide as an oral solution
Study: 20378999
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (half-dose trandolapril plus half-dose valsartan)
Study: 17977544
Drug: No danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No danazol treatment (Control)
Study: 11773543
Drug: Heliox therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox therapy (70% helium and 30% oxygen)